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ABSTRACT
Introduction Intensification of therapy has been 
associated with early worsening of retinopathy prior to 
subsequent risk reduction. We sought to assess whether 
glycated hemoglobin (HbA1c) reduction, following flash 
monitoring, was associated with early worsening.
Research design and methods An observational study 
in 541 individuals with type 1 diabetes and paired HbA1c 
and eye assessment prior to and following flash monitoring 
commencement.
Results Change in HbA1c was −4 mmol/mol (IQR −9–1) 
(−0.4% (−0.8–0.1)) and 25% achieved a fall in HbA1c of 
≥10 mmol/mol. The occurrence of the composite end point 
(panretinal photocoagulation, macular laser or anti- VEGF 
therapy) was associated with baseline HbA1c >75 mmol/
mol (9.0%) (HR 4.0 (95% CI 2.0 to 7.9), p<0.001) but not 
with fall in HbA1c of ≥10 mmol/mol (0.9%) (HR 1.6 (95% 
CI 0.8 to 3.2), p=0.203) over a follow- up period of 615 
days (527–863). In multivariate analysis, diabetes duration 
(p=0.035) and prior retinopathy (p<0.001) were most 
predictive of the composite end point. Baseline HbA1c 
was the strongest predictor of worsening retinopathy 
(p=0.002) or new retinopathy (p=0.002) in multivariate 
analysis whereas change in HbA1c was not independently 
associated with either (p=0.930 and p=0.830, 
respectively).
Conclusions Progression of eye disease is associated 
with baseline HbA1c, diabetes duration and previous 
retinopathy and such individuals should be monitored 
during intensification of glycemic therapy. Reassuringly, 
the extent of glucose lowering does not appear to be an 
independent risk factor for early worsening of eye disease 
in this context.
INTRODUCTION
Flash glucose monitoring provides users with 
an interstitial glucose value only on scan-
ning a glucose sensor with a reader device or 
compatible mobile phone. In other respects, 
it is similar to conventional continuous 
glucose monitoring (CGM) in providing a 
24 hours glucose trace and trend arrows.1 We 
have previously shown that flash monitoring 
is associated with clinically important reduc-
tion in glycated hemoglobin (HbA1c) in type 
1 diabetes, particularly in people with above 
target HbA1c at baseline.2 Flash monitoring 
is also known to reduce hypoglycemia and 
glucose variability in people with HbA1c ≤58 
mmol/mol (7.5%) prior to commencement. 
Intensification of glycemic control reduces 
the long- term risk of microvascular compli-
cations in type 1 diabetes,3 although, in the 
Diabetes Control and Complications Trial 
(DCCT), an early worsening of diabetic reti-
nopathy (EWDR) was observed before long- 
term, sustained risk reduction accrued.4 
Significance of this study
What is already known about this subject?
 ► Glycated hemoglobin (HbA1c) lowering has been as-
sociated with early worsening of diabetic retinopathy 
before risk reduction occurs.
What are the new findings?
 ► Baseline HbA1c and diabetes duration were asso-
ciated with subsequent need for intervention for 
diabetic eye disease and with the development or 
worsening of diabetic eye disease.
 ► Change in HbA1c was not greater in those with sub-
sequent panretinal photocoagulation, worsening of 
retinopathy or new development of retinopathy.
 ► When stratified based on HbA1c response, there 
were no differences in any eye outcomes when ad-
justed for baseline HbA1c.
How might these results change the focus of 
research or clinical practice?
 ► People with markedly elevated HbA1c, prior retinop-
athy and long diabetes duration require careful mon-
itoring after commencement of flash monitoring, but 
these data offer reassurance that extent of HbA1c 
lowering may not be a major contributor to risk.
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It is possible, however, that the method of intensifying 
glycemic control may influence the risk of early wors-
ening of diabetic eye disease. An analysis of recent CGM 
randomized controlled trials suggests that intensifica-
tion using CGM is associated with a significantly lower 
risk of hypoglycemia compared with self- monitored 
blood glucose (SMBG).5 Improved glycemic control, 
in the context of flash monitoring, is likely to be associ-
ated with lower rates of hypoglycemia and less glucose 
variability than was previously possible.6 Consequently, 
we hypothesized that improvement in glycemic control, 
following commencement of flash monitoring, may not 
independently predict early worsening of diabetic eye 
disease. To test this, we prospectively assessed the need 
for diabetic eye disease intervention (panretinal photo-
coagulation (PRP), macular laser or intravitreal anti-
vascular endothelial growth factor (VEGF) therapy) or 
progression/development of diabetic eye disease in a 
cohort of individuals commencing flash monitoring, with 
particular reference to achieved fall in HbA1c.
PARTICIPANTS AND METHODS
Study design and participants
We conducted a prospective observational study of the 
first 589 individuals with type 1 diabetes commenced on 
National Health Service (NHS) funded flash monitoring 
(Freestyle Libre, Abbott, Witney, UK) in a University 
hospital clinic (Royal Infirmary of Edinburgh) during 
February and March 2018. Glycemic outcomes for this 
cohort (including a group from another clinic within 
our center) have previously been reported, where the 
baseline characteristics are described in detail.2 In this 
current study, 14 individuals were excluded due to death 
or moving from the hospital catchment area, 14 were 
excluded due to absence of paired HbA1c data and a 
further 20 were excluded due to absence of paired eye 
outcome data, leaving a total cohort of 541 individuals 
(online supplemental figure). Two hundred twelve 
(39.2%) individuals had self- funded flash monitoring use 
prior to 2018 and provided their commencement date 
on a questionnaire. The study was entirely observational 
(with no deviation from standard clinical care) and ethics 
approval was not required.
Outcomes
The primary outcome was an assessment of factors asso-
ciated with the development of a composite end point 
comprising PRP, macular laser therapy or anti- VEGF 
therapy. Additional outcomes of interest were the indi-
vidual components of the composite outcome, new 
onset of retinopathy, new onset of maculopathy and 
worsening of retinopathy. Retinopathy was classified as: 
none, mild background, intermediate (any eye disease 
between mild background and proliferative, including all 
non- proliferative retinopathy and people with previous 
PRP and stable eye disease) or proliferative. Worsening 
retinopathy was defined as at least one step up through 
these categories, with the most advanced category being 
recorded for individuals when a discrepancy existed 
between eyes. Retinopathy and maculopathy data were 
obtained from the national diabetic retinopathy screening 
programme,7 which is accessible via our national clinic 
database system, SCI- Diabetes. In individuals attending 
specialist eye clinics, data on severity of eye disease and 
treatments administered were obtained from our hospi-
tal’s electronic health records. All individuals had a first 
eye assessment following flash monitoring with a further 
‘final’ assessment available in 397/541 (73.4%) (online 
supplemental figure). Change in HbA1c was defined 
as the difference between HbA1c prior to commence-
ment of any flash monitoring and the next available 
value after the flash monitoring education session (and 
change from baseline to the final available HbA1c). We 
also report the proportion of individuals achieving the 
Scottish HbA1c target (<58 mmol/mol (7.5%)). HbA1c 
was measured by ion- exchange high performance liquid 
chromatography using the Arkray Adams A1c automated 
platform (A. Menarini Diagnostics) and is typically 
measured every 6 months in people attending our clinics. 
Mode of insulin delivery (multiple daily injection (MDI) 
or continuous subcutaneous insulin infusion (CSII)), 
smoking status and urinary albumin status were obtained 
from SCI- Diabetes. Self- reported hypoglycemia data were 
available in 356/541 (65.8%) individuals from clinic 
questionnaires (including Gold score and a modification 
of the Clarke assessment8) completed within a year of 
commencing flash monitoring.
Statistical analysis
Data were largely non- normally distributed (as deter-
mined by Shapiro- Wilk test) and are presented as median 
and IQR. Paired data were analyzed by Wilcoxon signed- 
rank test and unpaired data by Mann- Whitney U test. Cate-
gorical data were analyzed by χ2 test or by Fisher’s exact 
test, when assumptions for χ2 test were not met. Logistic 
regression analysis was performed to identify associations 
with development or worsening of eye disease. Univariate 
analysis of the composite end point and need for PRP 
were assessed by log- rank test. Independent predictors of 
the composite end point and need for PRP were assessed 
by Cox proportional- hazard model. Significance was 
accepted at p<0.05. All analyses were performed using R 
Studio V.1.0.153.
RESULTS
Participant characteristics
Clinical and demographic characteristics are summarized 
in table 1. There was no significant difference between 
people achieving at least a 10 mmol/mol (0.9%) fall in 
HbA1c and those who did not, with the exception of base-
line HbA1c which was significantly higher in responders 
(72 mmol/mol (65–83) vs 61 (53–67)) (8.7% (8.1–9.7) vs 
7.7 (7.0–8.3), p<0.001).
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HbA1c and hypoglycemia
At baseline, 31.4% had an HbA1c <58 mmol/mol (7.5%) 
which rose to 48.6% at next follow- up after commencing 
flash monitoring (p<0.001). Median change in HbA1c 
was −4 mmol/mol (−9–1) (−0.4% (−0.8–0.1)) at next 
follow- up (median 253 days (156–507), p<0.001) and −3 
mmol/mol (−8–4) (−0.3% (−0.7–0.4)) at final follow- up 
(median 703 days (603–888), p<0.001). HbA1c reduc-
tion was more marked in individuals with HbA1c >75 
mmol/mol (9.0%) at baseline (−11 mmol/mol (−23–−5), 
p<0.001) (−1.0% (−2.1–−0.5)). At baseline, 31.4% had 
an HbA1c <58 mmol/mol (7.5%), which rose to 48.6% 
at next follow- up after commencing flash monitoring 
(p<0.001); 47.5% achieved an HbA1c fall of 5 mmol/
mol (0.5%) or greater (sustained until final follow- up in 
62.9%), 25.0% achieved a fall of 10 mmol/mol (0.9%) 
(sustained until final follow- up in 54.5%) and 8.1% 
achieved a fall of 20 mmol/mol (1.8%) (sustained until 
final follow- up in 52.5%). Self- reported hypoglycemia 
measures, following commencement of flash monitoring, 
were not significantly different in those achieving an 
HbA1c reduction of 10 mmol/mol (0.9%) and those who 
did not (online supplemental table 1).
Changes in diabetic eye disease
Median follow- up for occurrence of the composite end 
point (PRP, macular laser or anti- VEGF therapy) was 
615 days (527–863) from commencement of flash moni-
toring. During this time, 34 of 541 individuals experi-
enced an event at a median 218 days (112–469) from 
flash monitoring commencement, of whom 26 had a 
previous element of the composite end point prior to 
commencement (23 PRP, 10 macular laser, 6 anti- VEGF). 
Twenty- seven individuals required PRP following flash 
monitoring commencement (median 187 days (100–
382)), which was the first ever episode in 7/27 (details 
presented in table 2).
Three people received macular laser after flash moni-
toring all of whom had received previous macular laser 
for maculopathy previously. Nine people received anti- 
VEGF therapy after flash monitoring (median 222 days 
(186–542)), all of whom had maculopathy diagnosed 
prior to commencement and eight of whom had received 
previous laser treatment.
At next follow- up, since commencement of flash moni-
toring (median 235 days (135–344)), 430 (79.5%) had 
no change in their retinopathy status (none, mild back-
ground retinopathy, intermediate or proliferative). A 
deterioration was observed in 59 (10.9%) and improve-
ment in 52 (9.6%). Next follow- up was within 6 months in 
209/541 (47.3%) and within 12 months in 442 (81.7%). 
By final follow- up (n=397, median 615 days (527–863)), 
the corresponding figures were: no change in 279 
(70.3%), deterioration in 72 (18.1%) and improvement 
in 46 (11.6%). For maculopathy, at first assessment, no 
change was observed in 496 (91.7%), deterioration in 
28 (5.2%) and improvement in 17 (3.1%). The corre-
sponding maculopathy figures at final assessment were T
ab
le
 2
 
C
lin
ic
al
 fe
at
ur
es
 o
f i
nd
iv
id
ua
ls
 w
ith
 fi
rs
t 
ep
is
od
e 
of
 P
R
P
 o
cc
ur
rin
g 
af
te
r 
co
m
m
en
ce
m
en
t 
of
 fl
as
h 
m
on
ito
rin
g
A
g
e 
ra
ng
e 
(y
ea
rs
)
D
ia
b
et
es
 
d
ur
at
io
n 
(y
ea
rs
)
B
as
el
in
e
H
b
A
1c
(m
m
o
l/
m
o
l/
%
)
S
m
o
ki
ng
 
st
at
us
U
ri
ne
 
al
b
um
in
 
st
at
us
H
b
A
1c
 c
ha
ng
e 
at
 n
ex
t 
fo
llo
w
- u
p
 
(m
m
o
l/
m
o
l/
%
)
S
ev
er
e 
hy
p
o
g
ly
ce
m
ia
 in
 
p
re
vi
o
us
 y
ea
r
H
b
A
1c
 
ch
an
g
e 
at
 
fi
na
l f
o
llo
w
-  
up
M
D
I/
C
S
II
B
as
el
in
e 
re
ti
no
p
at
hy
 
st
at
us
D
ay
s 
fl
as
h 
m
o
ni
to
ri
ng
 
p
ri
o
r 
to
 P
R
P
Fi
na
l r
et
in
o
p
at
hy
 
st
at
us
D
ay
s 
fl
as
h 
m
o
ni
to
ri
ng
 t
o
 fi
na
l 
re
ti
no
p
at
hy
 s
ta
tu
s
1
30
–4
0
8
64
/8
.0
N
A
N
A
−
6/
−
0.
6
N
o
N
A
C
S
II
P
ro
lif
er
at
iv
e
15
5
M
ild
.b
ac
kg
ro
un
d
12
41
2
30
–4
0
14
83
/9
.7
N
ev
er
N
or
m
al
+
4/
+
0.
4
N
A
−
10
/−
0.
9
M
D
I
N
on
e
63
5
P
ro
lif
er
at
iv
e
67
8
3
30
–4
0
6
80
/9
.5
E
x
N
or
m
al
−
24
/−
2.
2
N
o
−
31
/−
2.
8
M
D
I
M
ild
 b
ac
kg
ro
un
d
38
7
N
on
-  p
ro
lif
er
at
iv
e
92
7
4
50
–6
0
32
66
/8
.2
C
ur
re
nt
N
or
m
al
−
8/
−
0.
7
N
o
N
A
M
D
N
on
- p
ro
lif
er
at
iv
e
10
76
P
ro
lif
er
at
iv
e
10
76
5
40
–5
0
21
57
/7
.4
E
x
N
or
m
al
−
2/
−
0.
2
N
A
+
12
/1
.1
M
D
I
M
ild
 n
on
- p
ro
lif
er
at
iv
e
76
7
P
ro
lif
er
at
iv
e
96
5
6
60
–7
0
8
84
/9
.8
E
x
N
or
m
al
−
22
/−
2.
0
N
A
0/
0
M
D
I
M
ild
 b
ac
kg
ro
un
d
16
5
N
A
N
A
7
30
–4
0
14
82
/9
.7
N
A
N
A
−
10
/−
0.
9
N
A
0/
0
M
D
I
M
ild
 b
ac
kg
ro
un
d
28
4
P
ro
lif
er
at
iv
e
12
28
C
S
II,
 c
on
tin
uo
us
 s
ub
cu
ta
ne
ou
s 
in
su
lin
 in
fu
si
on
; H
b
A
1c
, g
ly
ca
te
d
 h
em
og
lo
b
in
; M
D
I, 
m
ul
tip
le
 d
ai
ly
 in
je
ct
io
n;
 N
A
, n
ot
 a
va
ila
b
le
; P
R
P,
 p
an
re
tin
al
 p
ho
to
co
ag
ul
at
io
n.
copyright.
 on D
ecem
ber 4, 2020 by guest. P
rotected by
http://drc.bm
j.com
/
B
M
J O
pen D
iab R
es C
are: first published as 10.1136/bm
jdrc-2020-001668 on 1 N
ovem
ber 2020. D
ow
nloaded from
 
5BMJ Open Diab Res Care 2020;8:e001668. doi:10.1136/bmjdrc-2020-001668
Clinical care/Education/Nutrition
388 (97.7%), 3 (0.8%) and 6 (1.5%), respectively. Two 
hundred sixty- six individuals had no retinopathy at base-
line of whom 48 (18.0%) had developed retinopathy at 
next follow- up (all mild background).
Univariate analysis: associations with diabetic eye disease
Composite end point
Younger age at diagnosis (13 years (8–21) vs 19 (12–31), 
p=0.010), longer diabetes duration (27 years (24–38) 
vs 23 (12–36), p=0.001), higher HbA1c at baseline (74 
mmol/mol (57–81) vs 63 (55–71), p=0.006) (8.9% (7.4–
9.6) vs 7.9 (7.2–8.6)) and the presence of previous eye 
disease or treatments (table 3) were all associated with 
occurrence of the composite end point following flash 
monitoring. Change in HbA1c from baseline was not 
different between those requiring an intervention and 
those who did not (−5 mmol/mol (−17–−1) vs −4 (−9–1), 
p=0.163) (−0.5% (−1.6–−0.1) vs −0.4 (−0.8–0.1)) (table 3 
and figure 1A). The HR for the composite end point in 
those with high baseline HbA1c (>75 mmol/mol (9.0%)) 
was 4.0 (95% CI 2.0 to 7.9, p<0.001) (figure 2A), but 
there was no significant association in those with HbA1c 
fall ≥10 mmol/mol (0.9%) (HR 1.6 (95% CI 0.8 to 3.2), 
p=0.203) (figure 2C).
Panretinal photocoagulation
Younger age at diagnosis (13 years8–21 vs 19 (12–22), 
p=0.004), longer diabetes duration (27 years (22–36) vs 23 
(13–34), p=0.009), higher HbA1c at baseline (75 mmol/
mol (59–82) vs 63 (55–71), p=0.005) (9.0% (7.5–9.7) vs 
7.9% (7.2–8.6)) and the presence of previous eye disease 
or treatments (table 3) are all associated with the need 
for PRP following flash monitoring. Change in HbA1c 
from baseline was not different between those requiring 
PRP and those who did not (−4 mmol/mol (−15–0) vs −4 
(−9–1), p=0.548) (−0.4% (−1.4–0.0) vs −0.4 (−0.8–0.1)) 
(table 3 and figure 1B). The HR for the composite end 
point in those with high baseline HbA1c (>75 mmol/mol 
(9.0%)) was 4.7 (95% CI 2.1 to 10.0, p<0.001) (figure 2B) 
but there was no significant association in those with 
HbA1c fall ≥10 mmol/mol (0.9%) (HR 1.4 (95% CI 0.6 
to 3.2), p=0.368) (figure 2D).
Worsening retinopathy
Worsening retinopathy status at next follow- up was associ-
ated with higher baseline HbA1c (69 mmol/mol (48–81) 
vs 63 (55–71), p=0.010) (8.5% (6.5–9.6) vs 7.9 (7.2–8.6)) 
and lower frequency of retinopathy at baseline (18.6% 
vs 54.8%, p<0.001) at first follow- up. It was not signifi-
cantly associated with change in HbA1c following flash 
monitoring commencement (table 3 and figure 1C). At 
final follow- up, diabetes duration (26 years (17–37) vs 23 
(12–34), p=0.028) and lower frequency of retinopathy at 
baseline (22.2% vs 54.5%, p<0.001) were associated with 
worsening retinopathy (online supplemental table 2). 
The OR for the worsening retinopathy, at first follow- up, 
was 2.2 (p=0.012) in those with baseline HbA1c >75 
mmol/mol (9.0%) and 1.8 (p=0.045) in those with 
HbA1c fall ≥10 mmol/mol (0.9%).
New-onset retinopathy
New onset of retinopathy (all of which was mild back-
ground) was associated with longer diabetes duration (24 
years (14–33) vs 14 (8–30), p<0.001) and higher baseline 
HbA1c (65 mmol/mol (57–73) vs 61 (54–68), p=0.014) 
(8.1% (7.4–8.8) vs 7.7 (7.1–8.4)) but not change in HbA1c 
(−4 mmol/mol (−7–0) vs −3 (−9–−2), p=0.176) (−0.4 
(−0.6–0) vs −0.3 (−0.8–−0.2)) table 3 and figure 1D). No 
other parameters were significantly associated with new 
onset of retinopathy (table 3). At final follow- up, diabetes 
duration (25 years (15–37) vs 14 (8–29), p<0.001) and 
younger age at diagnosis (15 years (10–26) vs 26 (15–38), 
p<0.001) were associated with worsening retinopathy 
(online supplemental table 2). The OR for the new- onset 
retinopathy, at first follow- up, was 2.2 (p=0.065) in those 
with HbA1c >75 mmol/mol (9.0%) at baseline and was 
1.6 (p=0.173) for those with fall ≥10 mmol/mol (0.9%).
Multivariate analysis: associations with diabetic eye disease
Cox proportional- hazards analysis identified diabetes 
duration (HR 1.03 (95% CI 1.00 to 1.06) per year, 
p=0.035) and presence of baseline retinopathy (HR 6.58 
(95% CI 2.26 to 19.20), p<0.001) but not baseline HbA1c 
(HR 1.03 (95% CI 1.00 to 1.05), p=0.075) or change in 
HbA1c (HR 0.99 (95% CI 0.96 to 1.03), p=0.702) as inde-
pendently predictive of the composite end point.
Cox proportional- hazards analysis identified baseline 
HbA1c (HR 1.03 per mmol/mol (95% CI 1.01 to 1.06), 
p=0.015) and presence of baseline retinopathy (HR 11.5 
(95% CI 2.64 to 50.2), p=0.001) but not change in HbA1c 
(HR 1.01 per mmol/mol (95% CI 0.98 to 1.05), p=0.568) 
or diabetes duration (HR 1.02 per year (95% CI 0.99 to 
1.05), p=0.153) as independently predictive of subse-
quent PRP.
HbA1c at baseline (OR 1.04 per mmol/mol (95% CI 
1.01 to 1.06), p=0.002) and diabetes duration (OR 1.03 
per year (95% CI 1.01 to 1.05), p=0.005) but not change 
in HbA1c (OR 1.00 per mmol/mol (95% CI 0.97 to 1.04), 
p=0.830) were independently predictive of new develop-
ment of retinopathy in logistic regression analysis. HbA1c 
at baseline (OR 1.03 per mmol/mol (95% CI 1.01 to 
1.05), p=0.002) but not diabetes duration (OR 1.01 per 
year (95% CI 0.99 to 1.03), p=0.261) or change in HbA1c 
(OR 1.00 per mmol/mol (95% CI 0.97 to 1.03), p=0.930) 
were independently predictive of worsening retinopathy 
in logistic regression analysis.
DISCUSSION
We have demonstrated that HbA1c lowering, in the 
context of flash monitoring commencement, is not inde-
pendently predictive of clinically important changes in 
diabetic eye disease in the short- term. HbA1c prior to 
commencement of flash monitoring, as well as diabetes 
duration and pre- existing retinopathy were all inde-
pendently associated with progression of eye disease. 
copyright.
 on D
ecem
ber 4, 2020 by guest. P
rotected by
http://drc.bm
j.com
/
B
M
J O
pen D
iab R
es C
are: first published as 10.1136/bm
jdrc-2020-001668 on 1 N
ovem
ber 2020. D
ow
nloaded from
 
6 BMJ Open Diab Res Care 2020;8:e001668. doi:10.1136/bmjdrc-2020-001668
Clinical care/Education/Nutrition
Ta
b
le
 3
 
U
ni
va
ria
te
 c
om
p
ar
is
on
 o
f c
lin
ic
al
 fe
at
ur
es
 b
y 
oc
cu
rr
en
ce
 o
f c
om
p
os
ite
 e
nd
 p
oi
nt
, P
R
P,
 w
or
se
ni
ng
 r
et
in
op
at
hy
 a
nd
 n
ew
- o
ns
et
 r
et
in
op
at
hy
C
o
m
p
o
si
te
 e
nd
 
p
o
in
t
N
o
 c
o
m
p
o
si
te
 
en
d
 p
o
in
t
P
 v
al
ue
P
R
P
N
o
 P
R
P
P
 v
al
ue
W
o
rs
en
in
g
 
re
ti
no
p
at
hy
N
o
 w
o
rs
en
in
g
 
re
ti
no
p
at
hy
P
 v
al
ue
N
ew
 
re
ti
no
p
at
hy
N
o
 n
ew
 r
et
in
o
p
at
hy
P
 v
al
ue
N
=
34
N
=
50
7
N
=
27
N
=
51
4
N
=
59
N
=
48
2
N
=
48
N
=
21
8
M
al
e 
ge
nd
er
22
/3
4 
(6
4.
7%
)
25
5/
50
7 
(5
0.
3%
)
0.
10
4
18
/2
7 
(6
6.
7%
)
25
9/
51
4 
(5
0.
4%
)
0.
09
9
33
/5
9 
(5
5.
9%
)
24
4/
48
2 
(5
0.
6%
)
0.
44
1
25
/4
8 
(5
2.
1%
)
10
6/
21
8 
(4
8.
6%
)
0.
66
4
A
ge
 (y
ea
rs
)
45
 (3
5–
57
)
46
 (3
4–
57
)
0.
50
1
44
 (3
4–
56
)
46
 (3
4–
58
)
0.
87
3
48
 (3
5–
60
)
46
 (3
4–
57
)
0.
34
2
47
 (3
5–
59
)
45
 (3
0–
58
)
0.
40
3
A
ge
 a
t 
d
ia
gn
os
is
 
(y
ea
rs
)
13
 (8
–2
1)
19
 (1
2–
31
)
0.
01
13
 (8
–2
1)
19
 (1
2–
22
)
0.
00
4
18
 (1
2–
31
)
19
 (1
1–
30
)
0.
94
6
19
 (1
2–
31
)
23
 (1
4–
37
)
0.
19
5
D
ia
b
et
es
 d
ur
at
io
n 
(y
ea
rs
)
27
 (2
4–
38
)
23
 (1
2–
36
)
0.
00
1
27
 (2
2–
36
)
23
 (1
3–
34
)
0.
00
9
25
 (1
5–
35
)
23
 (1
3–
34
)
0.
30
2
24
 (1
4–
33
)
14
 (8
–3
0)
<
0.
00
1
B
as
el
in
e 
H
b
A
1c
 
(m
m
ol
/m
ol
/%
)
74
 (5
7–
81
)
63
 (5
5–
71
)
0.
00
6
75
 (5
9–
82
)
63
 (5
5–
71
)
0.
00
5
69
 (4
8–
81
)
63
 (5
5–
71
)
0.
01
65
 (5
7–
73
)
61
 (5
4–
68
)
0.
01
4
8.
9 
(7
.4
–9
.6
)
7.
9 
(7
.2
–8
.6
)
9.
0 
(7
.5
–9
.7
)
7.
9 
(7
.2
–8
.6
)
8.
5 
(6
.5
–9
.6
)
7.
9 
(7
.2
–8
.6
)
8.
1 
(7
.4
–8
.8
)
7.
7 
(7
.1
–8
.4
)
C
ha
ng
e 
in
 H
b
A
1c
 
(m
m
ol
/m
ol
/%
)
−
5 
(-
17
–-
1)
−
4 
(−
9–
1)
0.
16
3
−
4 
(−
15
–0
)
−
4 
(−
9–
1)
0.
54
8
−
4 
(−
12
–0
)
−
4 
(−
9–
1)
0.
22
6
−
4 
(−
7–
0)
−
3 
(−
9–
2)
0.
17
6
−
0.
5 
(−
1.
6–
0.
1)
−
0.
4 
(−
0.
8–
0.
1)
−
0.
4 
(−
1.
4–
0)
−
0.
4 
(−
0.
8–
0.
1)
−
0.
4 
(−
1.
1–
0)
−
0.
4 
(-
0.
8–
0.
1)
−
0.
4 
(−
0.
6–
0)
−
0.
3 
(−
0.
8–
0.
2)
H
b
A
1c
 fa
ll 
10
 
m
m
ol
/m
ol
 (0
.9
%
)
12
/3
4 
(3
5.
3%
)
12
3/
50
7 
(2
4.
3%
)
0.
15
9/
27
 (3
3.
3%
)
12
6/
51
4 
(2
4.
5%
)
0.
30
2
21
/5
9 
(3
5.
6%
)
11
4/
48
2 
(2
3.
7%
)
0.
04
5
15
/6
3 
(2
3.
8%
)
48
/2
18
 (2
2.
0%
)
0.
17
3
C
S
II
12
/3
4 
(3
5.
3%
)
13
5/
50
7 
(2
6.
6%
)
0.
27
1
10
/2
7 
(3
7.
0%
)
13
7/
51
4 
(2
6.
7%
)
0.
23
7
17
/4
2 
(2
8.
8%
)
13
0/
48
2 
(2
7.
0%
)
0.
76
3
16
/4
8 
(3
3.
3%
)
57
/2
18
 (2
6.
1%
)
0.
31
2
B
as
el
in
e 
re
tin
op
at
hy
30
/3
4 
(8
8.
2%
)
24
5/
50
7 
(4
8.
3)
<
0.
00
1
25
/2
7 
(9
2.
6%
)
25
0/
51
4 
(4
8.
6%
)
<
0.
00
1
11
/5
9 
(1
8.
6%
)
26
4/
48
2 
(5
4.
8%
)
<
0.
00
1
N
A
N
A
N
A
B
as
el
in
e 
m
ac
ul
op
at
hy
25
/3
4 
(7
3.
5%
)
70
/5
07
 (1
3.
8%
)
<
0.
00
1
18
/2
7 
(6
6.
7%
)
77
/5
14
 (1
5.
0%
)
<
0.
00
1
10
/5
9 
(1
6.
9%
)
85
/4
82
 (1
7.
6%
)
0.
89
6
N
A
N
A
N
A
P
R
P
 a
t 
b
as
el
in
e
23
/3
4 
(6
7.
6%
)
34
/5
07
 (6
.7
%
)
<
0.
00
1
20
/2
7 
(7
4.
1%
)
37
/5
14
 (7
.2
%
)
<
0.
00
1
4/
59
 (6
.8
%
)
53
/4
82
 (1
1.
0%
)
0.
31
9
N
A
N
A
N
A
M
ac
ul
ar
 la
se
r 
at
 
b
as
el
in
e
10
/3
4 
(2
9.
4%
)
18
/5
07
 (3
.6
%
)
<
0.
00
1
5/
27
 (1
8.
5%
)
23
/5
14
 (4
.5
%
)
0.
00
1
4/
59
 (6
.8
%
)
24
/4
82
 (5
.0
%
)
0.
78
1
N
A
N
A
N
A
A
nt
i-
 V
E
G
F 
at
 
b
as
el
in
e
6/
34
 (1
7.
6%
)
2/
50
7 
(0
.4
%
)
<
0.
00
1
3/
27
 (1
1.
1%
)
5/
51
4 
(1
.0
%
)
<
0.
00
1
2/
59
 (3
.4
%
)
6/
48
2 
(1
.2
%
)
0.
47
3
N
A
N
A
N
A
C
om
p
os
ite
 a
t 
b
as
el
in
e
26
/3
4 
(7
6.
5%
)
44
/5
07
 (8
.7
%
)
<
0.
00
1
20
/2
7 
(7
4.
1%
)
50
/5
14
 (9
.7
%
)
<
0.
00
1
8/
59
 (1
3.
6%
)
62
/4
82
 (1
2.
9%
)
0.
88
N
A
N
A
N
A
S
m
ok
in
g 
st
at
us
C
 3
/2
9 
(1
0.
3%
)
C
 4
9/
47
2 
(1
0.
4%
)
0.
99
1
C
 3
/2
3 
(1
3.
0%
)
C
 4
9/
47
8 
(1
0.
3%
)
0.
87
C
 1
/5
5 
(1
.8
%
)
C
 5
1/
44
6 
(1
1.
4%
)
0.
08
4
C
 1
/4
5 
(2
.2
%
)
C
 1
9/
20
0 
(9
.5
%
)
0.
26
4
E
 7
/2
9 
(2
4.
1%
)
E
 1
19
/4
72
 (2
5.
2%
)
E
 5
/2
3 
(2
1.
7%
)
E
 1
21
/4
78
 (2
5.
3%
)
E
 1
6/
55
 (2
9.
1%
)
E
 1
10
/4
46
 (2
4.
7%
)
E
 1
3/
45
 
(2
8.
9%
)
E
 5
0/
20
0 
(2
5.
0%
)
N
 1
9/
29
 (6
5.
5%
)
N
 3
04
/4
72
 
(6
4.
4%
)
N
 1
5/
23
 (6
5.
2%
)
N
 3
08
/4
78
 (6
4.
4%
)
N
 3
8/
55
 (6
9.
1%
)
N
 2
85
/4
46
 (6
3.
9%
)
N
 3
1 
(6
8.
9%
)
N
 1
31
/2
00
 (6
5.
5%
)
A
lb
um
in
 s
ta
tu
s
M
ac
ro
 0
/2
8 
(0
.0
%
)
M
ac
ro
 1
7/
45
0 
(3
.8
%
)
0.
78
3
M
ac
ro
 0
/2
2 
(0
.0
%
)
M
ac
ro
 1
7/
45
6 
(3
.7
%
)
0.
56
8
M
ac
ro
 5
/5
1 
(9
.8
%
)
M
ac
ro
 1
2/
42
7 
(2
.8
%
)
0.
03
7
M
ac
ro
 8
/1
92
 
(4
.2
%
)
M
ac
ro
 5
/4
1 
(1
2.
2%
)
0.
12
6
M
ic
ro
 2
/2
8 
(6
.1
%
)
M
ic
ro
 3
2/
45
0 
(7
.1
%
)
M
ic
ro
 1
/2
2 
(4
.5
%
)
M
ic
ro
 3
3/
45
6 
(7
.2
%
)
M
ic
ro
 4
/5
1 
(8
.2
%
)
M
ic
ro
 3
0/
42
7 
(7
.0
%
)
M
ic
ro
 1
1/
19
2 
(5
.7
%
)
M
ic
ro
 2
/4
1 
(4
.9
%
)
N
on
e 
26
/2
8 
(9
2.
9%
)
N
on
e 
40
1/
45
0 
(8
9.
1%
)
N
on
e 
21
/2
2 
(9
5.
5%
)
N
on
e 
40
6/
45
6 
(8
9.
0%
)
N
on
e 
42
/5
1 
(8
2.
4%
)
N
on
e 
38
5/
42
7 
(9
0.
2%
)
N
on
e 
17
3/
19
2 
(9
0.
1%
)
N
on
e 
34
/4
1 
(8
2.
9%
)
C
, c
ur
re
nt
; C
S
II,
 c
on
tin
uo
us
 s
ub
cu
ta
ne
ou
s 
in
su
lin
 in
fu
si
on
; E
, e
x-
 sm
ok
er
; H
b
A
1c
, g
ly
ca
te
d
 h
em
og
lo
b
in
; H
b
A
1c
, g
ly
ca
te
d
 h
em
og
lo
b
in
; N
, n
ev
er
 s
m
ok
ed
; P
R
P,
 p
an
re
tin
al
 p
ho
to
co
ag
ul
at
io
n;
 V
E
G
F,
 v
as
cu
la
r 
en
d
ot
he
lia
l g
ro
w
th
 fa
ct
or
.
copyright.
 on D
ecem
ber 4, 2020 by guest. P
rotected by
http://drc.bm
j.com
/
B
M
J O
pen D
iab R
es C
are: first published as 10.1136/bm
jdrc-2020-001668 on 1 N
ovem
ber 2020. D
ow
nloaded from
 
7BMJ Open Diab Res Care 2020;8:e001668. doi:10.1136/bmjdrc-2020-001668
Clinical care/Education/Nutrition
Intensification of glycemic management in type 1 
diabetes is unequivocally associated with reduction in the 
development and progression of diabetic retinopathy,3 9 10 
but those randomized to intensive glycemic control in 
the DCCT experienced EWDR prior to accruing substan-
tial and sustained benefit in the longer term.4 A number 
of potential pathophysiological mechanism have been 
posited to explain this phenomenon, including perturba-
tions of the somatotropic axis, increased retinal concen-
tration of VEGF and changes in other angiogenic growth 
factors.11 However, the evidence in support of these 
proposed mechanisms is, at best, mixed.
We hypothesized that advances in the management of 
type 1 diabetes since the early 1980s (eg, modern CSII, 
insulin analogues, aggressive blood pressure manage-
ment and ACE inhibitor prescribing) and specific 
features of intensification relating to flash monitor use 
may have reduced the risk of early worsening of eye 
disease following HbA1c reduction. Randomization to 
intensive glycemic control in DCCT was associated with 
a threefold increase in severe hypoglycemia while we did 
not, as previously reported, observe an increase in severe 
hypoglycemia following commencement of flash moni-
toring.2 RCT evidence attests to reduction in hypogly-
cemia (and glucose variability) during flash monitoring 
use6 in individuals with on- target HbA1c at baseline and 
similar findings have emerged from a large French obser-
vational study with respect to severe hypoglycemia.12 
Analysis of data from two recent real- time CGM studies, 
in MDI users, has suggested a significant attenuation of 
the increased risk of hypoglycemia as HbA1c levels fall, 
in contrast to those using SMBG.5 glycemic variability is 
another potential contributor towards risk of diabetes 
complications13 and has been associated with structural 
damage to the neuroretina in type 1 diabetes based on 
CGM measures of variability,14 while visit- to- visit vari-
ability in HbA1c has been independently associated 
with retinopathy progression in adolescents with type 
1 diabetes.15 Lending support to the potential impor-
tance of reduced glucose variability and hypoglycemia, 
early worsening of retinopathy has not been reported in 
the context of HbA1c reduction following islet16 17 and 
pancreas transplantation.18 Islet transplantation is associ-
ated with both reduced rates of hypoglycemia and lower 
glucose variability.19 Similarly, no significant progression 
of retinopathy was observed in a study of people with type 
1 diabetes following CSII commencement.20
The cohort described in our study is different from the 
DCCT cohort in a number of important respects: older 
age (46 vs 27 years), longer duration of diabetes (23 
vs 6 years) and higher prevalence of prior diabetic eye 
disease intervention (12.9% vs none in DCCT). Baseline 
Figure 1 Association between baseline glycated hemoglobin (HbA1c) and change in HbA1c following flash monitoring. (A) 
Composite end point in cohort with retinopathy at baseline. (B) Individuals requiring panretinal photocoagulation (PRP) in 
cohort with retinopathy at baseline. (C) Individuals with worsening retinopathy status in cohort with retinopathy at baseline. 
(D) Onset of new retinopathy in cohort with no pre- existing retinopathy. Orange dots represent events and green dots indicate 
individuals with no event.
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HbA1c (63 mmol/mol (7.9%) vs 76 mmol/mol (9.1%)) 
was lower in our study, although baseline HbA1c in those 
with a 10 mmol/mol (0.9%) or greater fall in HbA1c (72 
mmol/mol (8.7%)) was similar to the DCCT cohort. Our 
cohort is broadly representative of typical clinical practice 
in the UK, although, as previously described, it is slightly 
skewed toward lower than average HbA1c, younger age, 
CSII use and lower socioeconomic deprivation than our 
total clinic population.2
The study is open to the usual criticisms of observa-
tional methodology particularly the potential influence 
of unmeasured confounders. As a ‘real- world’ assessment, 
the timing of HbA1c measurement and eye assessment 
was not uniform and reflected the expected variation in 
normal clinical practice. A minority of individuals did 
not have an eye assessment within 1 year of flash moni-
toring commencement, meaning some early worsening 
may have been missed. Lack of uniformly timed HbA1c 
and eye assessments limits our ability to comment on the 
potential influence of rate of change in HbA1c. However, 
we have no reason to suspect variation in follow- up inter-
vals introduced any systematic bias. An advantage of this 
‘real- world’ methodology is its likely generalizability, in 
the absence of stringent exclusion and inclusion criteria, 
to modern diabetes clinic populations in the UK and 
beyond. The DCCT3 represents a landmark in method-
ologically robust evidence gathering in type 1 diabetes 
but the treatment options and risk factor management 
for the condition have evolved substantially since the 
1980s and, to our knowledge, our study represents the 
largest assessment of factors associated with early wors-
ening of eye disease in the context of modern intensifi-
cation of glycemic control. A significant limitation of our 
study is the absence of detailed Gold Standard evaluation 
of retinopathy, typically considered to be the Early Treat-
ment Diabetic Retinopathy Study (ETDRS) classification 
system.21 We relied on clinical data from our national 
screening programme7 and electronic health record 
entries from specialist eye clinic evaluation, which do 
not provide the same level of granularity as the ETDRS 
classification system. It is conceivable, therefore, that 
we have under- reported subtle changes in retinopathy. 
However, by relying on clinical data, we feel it is unlikely 
that we have missed clinically important changes and 
have also reported unambiguous hard end points (PRP, 
macular laser and anti- VEGF therapy). It is possible that 
we have missed an association between HbA1c lowering 
and EWDR because the degree of HbA1c reduction 
observed in this cohort is below the threshold at which 
this effect occurs, although this seems unlikely as none 
of the reported multivariate analyses of HbA1c reduc-
tion came close to approaching statistical significance. 
However, these data cannot exclude the possibility that 
more extreme reduction in HbA1c increases the risk of 
EWDR. It could also be argued that our results reflect 
a type 1 error, in refuting the independent association 
Figure 2 Survival curves stratified by baseline glycated hemoglobin (HbA1c) category (≤75 mmol/mol vs >75 mmol/mol). (A) 
Composite end point. (B) Panretinal photocoagulation (PRP). Survival curves stratified by baseline fall in HbA1c category (10 
mmol/mol or >10 mmol/mol) vs <10 mmol/mol). (C) Composite end point. (D) PRP. Vertical lines indicate censored data.
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between glucose lowering and early EWDR, due to insuf-
ficient cohort size or events. However, in multivariate 
analysis of the composite end point, new development 
of retinopathy and worsening of retinopathy, the absence 
of association was clear, consistent and not close to 
approaching statistical significance. The study benefits 
from comprehensive follow- up data and a wide range of 
associated clinical parameters derived from our national 
diabetes database, however, we were not able to report 
information on ACE inhibitor prescribing (and other 
antihypertensives) and pregnancy which would have 
been of interest in the context of diabetic eye disease.
CONCLUSIONS
Elevated HbA1c, longer duration of diabetes and pre- 
existing retinopathy are all significant risk factors with 
respect to diabetic eye disease in people with type 1 
diabetes commencing flash monitoring. However, in the 
short- term, subsequent change in HbA1c does not appear 
to independently predict the risk of retinopathy develop-
ment or progression nor the need for interventions to 
treat advanced eye disease in a representative cohort of 
flash monitoring users. These single- centre observational 
findings, while offering a degree of reassurance, clearly 
require corroboration from larger national datasets and 
randomized controlled trials of novel glucose- lowering 
technologies. Understanding the risk of abrupt reduc-
tion in HbA1c, as well as the potential moderating influ-
ence of hypoglycemia and glucose variability, will become 
increasingly important as we approach the era of closed- 
loop insulin delivery.
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Supplementary figure. Flow chart detailing missing data and follow-up intervals. 
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Supplementary Table 1. HbA1c and hypoglycaemia data following flash monitoring commencement stratified by HbA1c response. p refers to 
comparison between HbA1c response groups. Optimal bolus timing refers to people taking bolus insulin at least 15 minutes prior to meals. 
 
 Total cohort  
N = 541 
HbA1c fall 10 
mmol/mol (0.9%) or 
greater  
N = 135 
HbA1c change less 
than -10mmol/mol 
(0.9%) 
N = 406 
p 
Baseline HbA1c 
(mmol/mol / %) 
63 (55 – 72) / 7.9 
(7.2 – 8.7) 
72 (65 – 83) / 8.7 (8.1 – 
9.7) 
61 (53 – 67) / 
7.7 (7.0 – 8.3) 
 
<0.001 
Change in HbA1c 
(mmol/mol / %) 
-4 (-9 – 1) / 0.4 (-
0.8 – 0.1) 
-16 (-21 – -12) /  
1.5 (-1.9 – -1.1)  
-2 (-5 – 2) / 
0.2 (-0.5 – 0.2) 
<0.001 
Interval baseline to 
next HbA1c (days) 
384 (260 – 608) 399 (286 – 607)  376 (252 – 606) 0.533 
Optimal bolus timing 126/350 (36.0%) 40/89 (44.9%) 86/261 (33.0%) 0.042 
Severe hypo last year? 40/356 (11.2%) 13/89 (14.6%) 27/267 (10.1%) 0.245 
Symptomatic hypo 
more than weekly 
159/347 (45.8%) 36/89 (40.4%) 123/258 (47.4%) 0.238 
Asymptomatic hypo 
frequency once / 
month or more  
101/348 (29.0%) 26/87 (29.9%) 75/261 (28.7%) 0.838 
Impaired awareness 
hypoglycaemia? 
45/347 (13.0%) 14/88 (15.9%) 31/259 (12.0%) 0.342 
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Supplementary Table 2. Univariate comparison of clinical features by worsening retinopathy and new-onset retinopathy at final follow-up 
assessment.  
 
 Worsening retinopathy  No worsening 
retinopathy  
p New retinopathy  No new retinopathy  p 
Male gender 36/72 (50.0%) 174/325 (53.5%) 0.586 27/58 (46.6%) 72/146 (49.3%) 0.721 
Age (years) 46 (35 – 62)  46 (34 – 57) 0.585 46 (34 – 60) 47 (32 – 59) 0.983 
Age at diagnosis (years) 15 (10 – 25) 19 (11 – 31) 0.103 15 (10 – 26) 26 (15 – 38) <0.001 
Diabetes duration (years) 26 (17 – 37) 23 (12 – 34) 0.028 25 (15 – 37) 14 (8 – 29) <0.001 
Baseline HbA1c (mmol/mol / %) 64 (54 – 74)  
8.0 (7.1 – 8.9) 
63 (56 – 70) 
7.9 (7.3 – 8.6) 
0.684 62 (52 – 73) 
7.8 (6.9 – 8.8) 
61 (55 – 68) 
7.7 (7.2 – 8.4) 
0.527 
Change in HbA1c (mmol/mol / %) -5 (-12 – 1) 
-0.5 (-1.1 – 0.1) 
-4 (-9 – 0)  
-0.4 (-0.8 – 0)  
0.384 -4 (-12 – 1) 
-0.4 (-1.1 – 0.1) 
-3 (-9 – 1) 
-0.3 (-0.8 – 0.1)  
0.609 
HbA1c fall 10mmol/mol (0.9%) 23/72 (31.9%)   80/325 (24.6%) 0.199 17/58 (29.3%) 36/146 (24.7%) 0.494 
CSII 22/72 (30.6%) 93/325 (28.6%) 0.743 17/58 (29.3%) 41/146 (28.1%) 0.861 
Any retinopathy present at 
baseline 
16/72 (22.2%) 177/325 (54.5%) <0.001 NA NA NA 
Any maculopathy present at 
baseline 
16/72 (22.2%) 54/325 (16.6%) 0.259 NA NA NA 
PRP at baseline 9/72 (12.5%) 39/325 (12.0%) 0.906 NA NA NA 
Macular laser at baseline 8/72 (11.1%) 17/325 (5.2%) 0.063 NA NA NA 
Anti-VEGF at baseline 3/72 (4.2%) 5/325 (1.5%) 0.331 NA NA NA 
Composite at baseline 15/72 (20.8%) 44/325 (13.5%) 0.115 NA NA NA 
Smoking status Current 6/65 (9.2%) 
Ex 17/65 (26.2%) 
Never 42/65 (64.6%) 
Current 35/302 
(11.6%) 
Ex 71/302 (23.5%) 
Never 196/302 
(64.9%) 
0.809 Current 4/52 (7.7%) 
Ex 11/52 (21.2%) 
Never 37/52 
(71.2%) 
12/137 (8.8%) 
37/137 (27.0%) 
88/137 (64.2%) 
0.660 
Albumin status Macro 5/60 (8.3%) 
Micro 4/60 (6.7%) 
None 51/60 (85.0%) 
Macro 9/292 (3.1%) 
Micro 25/292 (8.6%) 
None 258/292 
(88.4%) 
0.154 Macro 4/48 (8.3%) 
Micro 1/48 (2.1%) 
None 43/48 (89.6%) 
Macro 7/132 (5.3%) 
Micro 11/132 (8.3%) 
None 114/132 
(86.4%) 
0.268 
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